Allurion Technologies (ALUR) investor relations material

Executive summary

• Announced a strategic pivot to focus on low-dose GLP-1 combination therapy, muscle mass maintenance, and U.S. market entry, with a term sheet signed for expanded manufacturing and R&D.

• Revenue for Q2 2025 was $3.4M, down 71% year-over-year, mainly due to distributor transitions and temporary suspension in France.

• Significant cost reductions in sales, marketing, R&D, and G&A followed restructuring and workforce reductions.

• Submitted the final module of the PMA to the FDA, with supportive data exceeding key clinical endpoints and FDA acceptance for review.

• Completed a restatement of prior financials due to errors in comprehensive income and other items, with no impact on revenue or operating loss.

Financial highlights

• Q2 2025 revenue was $3.4M, down from $11.8M year-over-year, with gross profit of $2.5M (74% margin) and operating loss improved to $7M from $9.3M.

• Operating expenses decreased 48% year-over-year, with all major categories significantly reduced.

• Cash and equivalents stood at $12.7M as of June 30, 2025.

• Net cash used in operations for the first half of 2025 was $17.1M.

• Net loss for Q2 2025 was $9.3M; net loss per share was $(1.28) with 7.3M shares outstanding.

Outlook and guidance

• Guidance for 2025 is under reevaluation due to near-term disruption from the strategic pivot and restructuring.

• Operating expenses expected to decrease by approximately 50% following restructuring, with a 65% workforce reduction by Q3 2025.

• Management expects continued operating losses and negative cash flows, with substantial doubt about the ability to continue as a going concern.

• FDA approval timeline for the PMA may be shorter than the initial 12-month estimate due to modular submission and strong data.

• Ongoing efforts to regain NYSE compliance and secure additional capital.